A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndromeAzra Raza, Mikkael A. Sekeres, Mark U. Rarick et al.|Cancer|2011Cited by 44
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)Azra Raza, Ruben A. Mesa, Naomi Galili et al.|Journal of Hematology & Oncology|2012Cited by 27
A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML)Abbas Raza, Aaron D. Schimmer, Naomi Galili et al.|Journal of Clinical Oncology|2009Cited by 8
Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Azra Raza, Mikkael A. Sekeres, Naomi Galili et al.|Blood|2010Cited by 2